J.P.Morgan

In a report published Tuesday, J.P. Morgan analyst Alistair J. Meadows initiated coverage on Atlas Resource Partners (NYSE: ARP) at Neutral and established a $24 price target. In the report, J.P. Morgan noted, "Since spinning out of Atlas Energy, L.P. (ATLS), ARP has been able to grow the...

According to a research report this morning, J.P. Morgan initiates an Overweight rating and a $24 PT on the leading provider of voice/audio processors, Audience (NASDAQ: ADNC). J.P. Morgan stated, “With exposure to the fast growing smartphone/tablet markets, the company has a significant market...

According to a research report this morning, J.P. Morgan initiates a Neutral rating and a $10 PT for retail real estate company, Retail Properties of America (NYSE: RPAI). J.P. Morgan stated, RPAI (formerly known as Inland Western) was a non-traded REIT prior to its April 2012 equity offering/...

According to a research report this morning, J.P. Morgan raises PO on Texas Roadhouse (NASDAQ: TXRH) from $19 to $20 following a strong 1Q and an overall outperformance. J.P. Morgan stated, “We are updating our model to reflect TXRH 1Q results. Traffic-driven comps are outperforming the rest of...

According to a research report this morning, Honeywell (NYSE: HON) is in the better-than-expected 2Q range and it continues to increase its value. J.P. Morgan stated, “EPS of $1.04 was $0.05 ahead of Consensus with segment profits $0.08 ahead of our model, and results included an additional ~$0.02...

According to a research report this morning, M&T Bank (NYSE: MTB) finished out 1Q12 with a strong EPS of $1.51, blowing away estimates of $1.46. J.P. Morgan stated, “Overall pre-tax, pre-provision results were in line with expectations, although a much stronger than expected quarter for...

A report from J.P. Morgan reiterates its Overweight rating on Albemarle (NYSE: ALB). The report states, “Albemarle reported 3Q:11 EPS of $1.28 versus $1.02 in the year-ago quarter, and our forecast of $1.21. The Bloomberg Consensus was $1.18. Our EPS forecast did not reflect the $0...

A report from J.P. Morgan reiterates its Neutral rating and $23 price target on Owens-Illinois (NYSE: OI). The report states, “Improving execution can partially close the gap; however, we see some structural challenges that need to be considered (e.g. price/cost lags in inflationary environment)...

J.P. Morgan, citing a strong F2Q12 from the company, is lowering its price target on salesforce.com (NYSE: CRM) from $140 to $130, but is maintaining its Neutral rating on the stock. Says J.P. Morgan, in the report, “CRM reported strong F2Q12 results, posting continued momentum in new business...

According to J.P. Morgan, Penske Automotive Group (NYSE: PAG) Neutral rating is maintained. J.P. Morgan said that it left FY2011 and FY2012 EPS unchanged primarily because we are now penciling higher SG&A. “We continue to expect gross margins of new and used vehicles to decline as inventories...

According to J.P. Morgan, UnitedHealth Group (NYSE: UNH) reported 2Q EPS at $1.16, about $0.27 ahead of estimate, while ex a potential $0.15 charge we had incorporated, the report would have come in $0.12 ahead. J.P. Morgan said that, much like prior quarters, the upside was mostly on lower...

J.P. Morgan has published a research report on Omnicom Group (NYSE: OMC) noting positive Q2 results. In the report, J.P. Morgan commented, "We expect strong revenue growth and positive commentary on the health of the ad industry when Omnicom reports 2Q results on Tuesday, July 19th. We believe...

J.P. Morgan is maintaining its Neutral rating and $53 price target on Citrix Systems (NASDAQ: CTXS) following the company's recent analyst meeting. According to J.P. Morgan, “We attended CTXS' financial analyst meeting held in conjunction with the company's annual Synergy conference in San...

J.P. Morgan has raised its price target on Pharmasset (NASDAQ: VRUS) from $100 to $200 in light of “Biotech Week”Day 2 and portfolio analysis of the stock. According to J.P. Morgan, “[The change in price target] is based on consistent positive feedback from the Hep C arena and building momentum...

In a recent report, J.P. Morgan has raised the price target on Tornier N.V. (NASDAQ: TRNX) from $26.00 to $30.00 and reiterated an Overweight rating on the company after J.P. Morgan spent a few days on the road with TRNX. In the report, J.P. Morgan said, "The tone was notably upbeat, as the...